First Republic Capital

Canntab Therapeutics IN THE NEWS (Equity.Guru) – Canntab Therapeutics (PILL.C): The Canadian weed sector is struggling, but new consumer products have room to scale

01/21/2021

If we’re honest about it – if we’re REALLY honest about it – Canada has fumbled its advantage in the cannabis sector. First to market, first to raise hundreds of millions in financing, first to legalize, first to recreationalize (not a word but I’m on a roll), and it’s all really been for naught.

In a sector where the law says you’re not allowed to market yourself, low prices offer one of the few ways to grow market share while also kicking off a race to the bottom. Premium suppliers would suggest they have an advantage, but since they can’t advertise that premium status in a meaningful way, they have to rely on word of mouth and organic growth which, with hundreds of competitors vying for space, isn’t a path to riches.

The cannabis products available in Canada are hemmed in by hand wringing legislators and regulators, the black market continues to thrive, and quality standards are a long way from the old days of ‘BC Bud’ being world renowned as the cream of the crop.

And even if all of the above doesn’t put you off the Canadian weed market, purchase limits and potency restrictions force heavier users to either make daily purchases to keep their cupboards filled, or stick with the guy behind the dumpster who they used to buy from in the 90’s. Meanwhile, retail is hamstrung and bottlenecked by government distribution models and retail rules that force you to lock your product in plastic bubbles and wrap it in adult-proof, waste-heavy packaging.

  • What we wanted: High quality, inexpensive, adult products for adults, sold at suburban retail stores and online by a burgeoning industry leading the world.
  • What we got: Low quality, low impact products that cost too much, frequently run out at the government dispensary, and have to be signed for at the post office, while LPs continue to struggle to make profits and the US market skyrockets.

So if everything is awful on the Canadian scene, why am I writing a story about a Canadian cannabis company?

Because PRODUCTS, man.

Look, anyone in Canada who wants to smoke weed has now done so. The scalability of that market only exists in as much as you can convince people who have never smoked week to start doing so now. That’s tough going. The folks I know who aren’t traditional marijuana enthusiasts but wouldn’t mind a buzz or a health boost, want gummies, chocolates, beverages at a push, drops, and capsules. We don’t take wine to a BBQ anymore, we take edibles.

But all of the above have a major problem in that those products are notoriously unreliable. Drop a gummy, notice no effect, drop another and your face melts off. Share chocolates with your friend, watch her roll around giggling while you’re thinking about your taxes.

Just last night, as I was prepping this story, I took a little edible before bed to get some smooth sleep, and the next morning I was still tripping balls.

ENOUGH. I want a measured dose of the good stuff with a time release, from a trustworthy supplier, so I can microdose and not disappear into my couch. But there’s no real option for me in Canada.

The existing capsules out there are, to say the least, janky.

The capsules to the right are Dosecann’s product, and they’re fine I guess, but they’re mostly a CBD hit. The gelcaps put out by Daily Special, Redecan, Tweed and others are also either CBD hits, or 5mg of more of THC – good to get you high, not so great as a microdose option.

The problem is, these options aren’t slow release. You hit ’em, and they hit you back. If they have a consistent and accurate dose, that’s a win, but they don’t always. And because getting them to you in Canada is an expensive and annoying exercise, a 1mg THC option doesn’t make financial sense.

If only there were someone, somewhere, that could provide a slow release, pressed pill option, with total accuracy and consistency such as you’d find in a big pharma medical product?

Hell, if a company like that existed, and had defendable IP related to that product, well that could be a monster.

WHAT’S UP CANNTAB THERAPEUTICS (PILL.C).

Canntab Therapeutics is the industry leader in solid oral dose formulations of cannabis with a product line of cannabinoid (THC & CBD) and terpenoid blends in exacting dosages. With one US Patent granted on September 17th of this year, and 13 more patents pending in Canada and the United States, we are well positioned to dominate the medical cannabis market with a range of hard pill cannabinoid formulations that provide doctors and patients with a medical grade solution not currently available.

Click Here to Continue Reading

Red Light Holland Announces Intention to Acquire Controlling Interest in Psychedelic Insights Providing Psychological Guidance of Psychedelic Experiences with Truffles in the Netherlands

Toronto, Ontario–(Newsfile Corp. – December 9, 2020) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC: TRUFF) (“Red Light Holland“) is pleased to announce it has entered into a non-binding letter of intent to acquire 51% of Psychedelic Insights in Amsterdam, the Netherlands. Psychedelic Insights currently provides psychedelic assistance to clients from all over the world, who are in need and wanting to try a safe and psychological guided experience. Psychedelic Insights’ dedicated and compassionate facilitators, including a team of psychiatrists, psychologists, therapists and scientists, provide psychological guidance of psychedelic experiences in many different categories including: (i) individuals or small groups (ii) psychedelic palliative care (iii) Re-connecting Veterans and (iv) provides global mental health screening. Psychedelic Insights portfolio also includes unique therapist training and psychedelic assisted leadership coaching.

As part of the expected 51% acquisition, a condition in the agreement will include: an exclusive supply agreement with Red Light Holland’s Truffles, grown from Red Light Holland’s facility in Horst, Netherlands with the intention to be used solely by Psychedelic Insights’ clients.

“I find it so interesting that behind the scenes we’ve been working on this deal for months in the Netherlands, and we just happened to agree to it on the same day Canada granted 17 healthcare professionals to possess and use psilocybin for professional training in psilocybin therapy,” said CEO Todd Shapiro. “Luc Van Poelje, CEO of Psychedelic Insights and his team have a very professional and compassionate business and we are looking forward to potentially helping it grow, because of the capital Red Light Holland can provide. There is a careful due diligence process, but we are very excited at this potential to create another alternative revenue stream as we stay true to our mission of helping people gain access to psilocybin via our Red Light Holland Truffles, responsibly.”

“Our team of psychiatrists, psychologists, therapists and scientists at Psychedelic Insights are all excited to potentially be partnering with Red Light Holland so we can continue to grow our psychedelic assisted service to clients from all over the world, who are in need and wanting to try a safe and psychologically guided experience. Our dedicated and compassionate facilitators are also pleased to potentially use Red Light Holland’s Truffles, exclusively and are pleased at this intention to grow our business so ultimately we can hopefully help more people in need,” added Luc Van Poelje, CEO Psychedelic Insights.

Recently, Red Light Holland announced a non-binding letter of intent with Halo Labs Inc. (“Halo“) for the purposes of creating a joint venture to become a licensed psilocybin manufacturer to supply psilocybin products to licensed service centers in the State of Oregon, and to explore other potential business opportunities in this new regulated market, subject to compliance with all applicable Oregon laws and regulations. The planned acquisition of a majority interest in Psychedelic Insights in The Netherlands keeps in line with the aforementioned theme and future plans of Red Light Holland’s potentially being involved (in multiple countries) in legal psilocybin-assisted initiatives.

Click Here to Continue Reading

Gratomic Announces Aukam Graphite Property Construction Update

The Gratomic team has completed the excavations intended to contain the concrete foundations that will accommodate the custom designed processing equipment including material thickener, cyclone, material hopper, settling reservoir, and filter press. Gratomic is currently preparing to begin pouring concrete in these areas the second week of October.

The current pilot sump area will be designated to house the new floatation columns and mixing tanks. The filter press area has been prepared and excavation is currently scheduled to begin October 6th on the product dryer area.

Final general assembly and layout of the Aukam processing plant have been completed. On site Management has received the cement from Pupkewitz Megabuild – Keetmanshoop. Aggregate and bricks were received from Dolerite Brick & Sand CC, which will be utilized in the construction of the settling reservoir and key foundations.

Manhattan Process Engineering, a South African based engineering firm, has provided the Company with detailed Civil Engineering reports to complete the concrete construction on site. This included detailed bending and manufacturing parameters to meet foundational specifications for the necessary rebar, which has recently been delivered to site.

Click Here to Continue Reading

FSD Pharma Begins Phase 2 Clinical Trial to Evaluate FSD201 for the Treatment of Hospitalized COVID-19 Patients

– FDA has authorized randomized, controlled, double-blind, multicenter study on 352 patients

TORONTO, ON / ACCESSWIRE / September 28, 2020 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE.CN) (“FSD Pharma” or the “Company“) today announced that the U.S. Food and Drug Administration (“FDA“) has authorized the initiation of a Phase 2 study for the use of FSD201 (ultramicronized palmitoylethanolamide, or ultramicronized PEA) to treat COVID-19, the disease caused by the SARS-CoV-2 virus (the “FSD201 COVID-19 Trial“). The company is expected to start dosing patients in October 2020. We believe FSD201 may have the potential to address the over-exuberant inflammatory response characterized by COVID-19 infection that may lead to a cytokine storm and ultimately death.

“Commencing a phase 2 clinical trial to treat hospitalized COVID-19 patients is a major milestone achieved by our pharmaceutical team led by Dr. Edward Brennan and a huge step forward for FSD Pharma,” said Dr. Raza Bokhari, Executive Co-Chairman & CEO. We are joining the global fight against the deadly SARS-CoV-2 virus with a hope to demonstrate down-regulation of the over-expressed immune response in COVID-19 patients leading to better treatment outcome. FSD201 is formulated as a tablet for oral dosing and is a safe compound with no known serious adverse side effects. Numerous studies over the past 40 years have validated micronized PEA for its efficacy and safety in the treatment of, and prophylactic effects with respect to, other respiratory infections.”

Click Here to Continue Reading

Canntab Granted 1st US Patent Covering Multi-Layer (Bi-Layer) Tablets

TORONTOSept. 21, 2020 /CNW/ – Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the “Company” or “Canntab“), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is thrilled to announce that, pursuant to a filing made in March 2017, the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,772,837 to Canntab, titled “Modified Release Multi-Layer Tablet Cannabinoid Formulations. The term of the patent expires on March 15, 2038.

Larry Latowsky, CEO of Canntab said “this is a major milestone that confirms our proprietary formulations are unique and differentiated from other product offerings in the global marketplace which will support a faster revenue stream as we begin production and distribution in the immediate future. This is the first patent that was issued to date out of the 13 that we have applied for, and will be leveraged to solidify Canntab’s position as the leader in solid dose (hard pill) formulations of medicinal cannabinoids.

The patent granted is for Canntab’s bi-layer or multi-layer tablets consisting of both Instant Release (“IR”) and Extended Release (‘XR”) formulations with THC, CBD and a variety of Terpenes and other Cannabinoids found in full spectrum Cannabis and Hemp oil resin.

Canntab believes that its hard pill formulations are superior to all other CBD and THC delivery systems since they are true pharmaceutical grade delivery systems which provide for superior ingredient stability, enhanced bioavailability, and provide customizable and precise dosing. Canntab believes and intends to prove greater bioavailability through a blood level study at a 3rd party Clinical Research Organization (CRO). In addition, whether it is for medical, recreational or nutraceutical purposes, Canntab is able to provide extended release formulations making it the clear delivery choice for doctors, patients or the average consumer.

“Canntab expects this and future patents to be very valuable in the development of our strategic partnerships and alliances and in our efforts to secure worldwide distribution of our proprietary products. As the medical community continues to recognize Cannabinoid alternatives to traditional therapies, we will continue to develop innovative approaches to support many clinical applications” continued Latowsky.

In addition, Canntab is conducting research to confirm its belief that its combined CBD and THC tablet can be effective to treat nicotine, alcohol, cannabis, opioid and other forms of addiction. Canntab will be using a derivative of these formulations for its clinical trial with Dr. Donald Garbuz from the University of British Columbia and as previously released in December 2018. This study aims to demonstrate the potential for the reduction or elimination of the use of opiates in patients during post-operative pain management.

Click Here to Continue Reading.

Red Light Holland’s Science and Innovation Division, Scarlette Lillie Joins Medical Psychedelics Working Group with Leading Academics; Professor David Nutt and Professor Jo Neill

Toronto, Ontario–(Newsfile Corp. – September 17, 2020) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC: TRUFF) (“Red Light Holland” or the “Company“), an Ontario-based corporation positioning itself to engage in the production, growth and sale of its brand of magic truffles to the legal, recreational market within the Netherlands, is pleased to announce that Red Light Holland’s Science and Innovation division, Scarlette Lillie Science and Innovation (“Scarlette Lillie“), has joined the Medical Psychedelics Working Group (“MPWG“), a consortium of drug science experts, leading academics and researchers, policy specialists and industry partners. MPWG’s aim is to create a rational and enlightened approach to psychedelic research and clinical treatment. MPWG will explore innovation within the psychedelic space with a specific focus on how psychedelics can be integrated into primary and secondary healthcare. The Company believes that evidence-based science, sharing data, and strong partnerships are keys to success for the psychedelic community.

“We are elated to join the most respected experts in the industry. To be able to have open communication with leading academics like Professor David Nutt, Dr. Robin Carhart-Harris and Dr. Jo Neill is a major development for Scarlette Lillie Science and Innovation. Access is key in life and having access to the top minds in this sector is something we are all very excited about,” said Red Light Holland CEO and Director, Todd Shapiro.

“When we were approached by Red Light Holland’s Scarlette Lillie Science and Innovation, we were more than happy to include them in this very important working group. We are grateful for their support and we recognize the Company’s genuine and authentic approach to helping make positive change in this world through psilocybin research, education and information. We are thrilled to have Scarlette Lillie join our very MPWG,” stated Professor Jo Neill.

“Both Sarah Hashkes and I are pleased to be able to brainstorm and continue developing these important synergies with our peers in the field of Medical and Science Research to help elevate the Psychedelic Sector as a whole,” added Dr. Joe Geraci, Scarlette Lillie’s Scientific Advisor and CEO of Netramark.

 

Click Here to Continue Reading

Gratomic Aims to Become a Cleaner Source of Graphite for North American Consumers

TORONTO, ON / ACCESSWIRE / September 3, 2020 / Gratomic Inc. (“GRAT” or the “Company”) (TSXV:GRAT)(OTC PINK:CBULF)(FRANKFURT:CB81) (WKN:A143MR) aims to become a cleaner graphite source for North American consumers and is pleased to announce the Company’s objective to process graphite in a clean and environmentally responsible manner.

As the battery manufacturing industry becomes increasingly competitive, many electric vehicle battery manufacturers are currently forced towards choosing lesser environmentally friendly graphite options. In many cases, the mining and processing methods used can be unsafe and some have the potential to cause major pollution in neighbouring cities and towns. Alternatively, many electric vehicle battery manufacturers are turning to synthetic graphite sources, often created in labs from petroleum and biogas by-products, among other carbon sources. These methods can also potentially produce undesirable emissions during the processing phase.

Click Here to Continue Reading

Red Light Holland Announces Arrangement to Launch Sale of Psychedelic Truffle Microdosing Packs in the Netherlands

Toronto, Ontario–(Newsfile Corp. – September 2, 2020) – Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (“Red Light Holland” or the “Company“), an Ontario-based corporation positioning itself to engage in the production, growth and sale of its brand of magic truffles to the legal, recreational market within the Netherlands, is pleased to announce that it has solidified its arrangement with McSmart (as defined by the listing statement) for the launch of its previously announced Microdosing Packs through three Smart Shops operated by McSmart. The Microdosing Packs are anticipated to become available for purchase to consumers in the Netherlands before the end of September 2020, at the following Smart Shop locations: (i) two Tatanka locations, and (ii) the Headshop. In addition, the Microdosing Packs are also expected to become available for purchase in the Netherlands on Tatanka’s website at www.tatanka.nl.

“All of us at Red Light Holland are very excited as our Microdosing Packs are so close to being on shelves and available for online purchases. We are still anticipating our premiere product launch, with our newly coined phrase “iMicrodose,” happening later this month, and working so closely with McSmart is something we are truly appreciative of,” said Todd Shapiro, Chief Executive Officer and Director of the Company.

Magic truffles, which are sold in their natural, raw and unprocessed form, need to be refrigerated. As such, two of the Smart Shops are also expected to feature Red Light Holland-branded fridges to house the magic truffles and display their iMicrodose packs in a clever and unique way. The Microdosing Packs have a shelf-life of approximately 3 months.

FSD Pharma to Ring Nasdaq Opening Bell on Wednesday, January 22, 2020

TORONTOJan. 17, 2020 /CNW/ – FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”) is pleased to announce that Executive Co-Chairman and CEO Dr. Raza Bokhari, along with the founders, members of the Company’s Board of Directors, members of the leadership team, early investors, advisors, and other stakeholders, will ring the Nasdaq Stock Market opening bell on Wednesday, January 22, 2020, at 9:30 am ET.

The Opening Bell Ringing Ceremony will be held at Nasdaq’s MarketSite in New York City and will be webcast live beginning at 9:20 am ET via the following link: https://www.nasdaq.com/marketsite/bell-ringing-ceremony and live streaming will be available on Facebook at the following link: http://Facebook.com/Nasdaq.

“It will indeed be a unique privilege for me to ring the opening bell at Nasdaq to commence trading in the presence of FSD Pharma’s extended family and friends,” said Raza Bokhari, MD, Executive Co-Chairman and CEO. “The recent listing of our Class B Subordinate Voting Shares on Nasdaq has included us in a select group of 12 Canadian-domiciled cannabis companies that trade on a major U.S. exchange. I am, however, very hopeful that sooner rather than later we will  be placed in a league of our own as we continue to demonstrate that the primary thrust of our business is to focus on conducting clinical trials on synthetic compounds with anti-inflammatory properties that target the CB2 receptor of the endocannabinoid system of the human body.”

FSD Pharma to Commence Trading on Nasdaq Capital Market Under Symbol ‘HUGE’

TORONTO — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) (“FSD Pharma” or the “Company”) announced that its Class B Subordinate Voting Shares (the “Shares”) will commence trading on the Nasdaq Capital Market under the symbol ‘HUGE’ today, January 9, 2020. The Company’s Class B Subordinate Voting Shares will continue to trade on the Canadian Securities Exchange under the symbol ‘HUGE’.

“The listing of our shares on the Nasdaq Capital Market is a momentous moment and represents a paradigm shift in the outlook of FSD Pharma,” said Dr. Raza Bokhari. “Doing so offers us an opportunity to expand awareness of the company’s specialty pharmaceutical lead asset, a micronized formulation of palmitolylethonalamide (micro-PEA), which by targeting the CB2 receptor of the endocannabinoid system of the human body, may help address the opioid crisis by developing opioid-sparing, FDA-approved prescription drugs. A NASDAQ listing also elevates our corporate profile to institutional investors.”

Dr. Bokhari will present at Biotech Showcase 2020 in San Francisco on Monday, January 13, 2020 at 3:30 pm PT where he will provide an overview of the Company, as well as recent strides made to transform FSD Pharma into a specialty pharmaceutical R&D company.

Dr. Bokhari and members of the FSD Pharma leadership team will also meet with members of the global investment community while in San Francisco from January 13 to 15, 2020 on the sidelines of the JPMorgan 38th Annual Healthcare Conference.